Provided by Tiger Fintech (Singapore) Pte. Ltd.

Larimar Therapeutics, Inc.

2.91
+0.25009.40%
Post-market: 2.910.00000.00%16:00 EDT
Volume:1.89M
Turnover:5.51M
Market Cap:186.32M
PE:-1.95
High:3.06
Open:2.71
Low:2.65
Close:2.66
Loading ...
May 17, 2021

Major Issues Report

8-K - Current report
May 11, 2021

Major Issues Report

8-K - Current report
May 10, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 10, 2021

Major Issues Report

8-K - Current report
Mar 04, 2021

Major Issues Report

8-K/A [Amend] - Current report
Mar 04, 2021

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 04, 2021

Major Issues Report

8-K - Current report
Mar 02, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 16, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 16, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 16, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 16, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 16, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 16, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 12, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 11, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 02, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Dec 08, 2020

Major Issues Report

8-K - Current report
Nov 12, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 12, 2020

Major Issues Report

8-K/A [Amend] - Current report